Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Ohm Laboratories, a subsidiary of Ranbaxy, announced it has received approval from the FDA to manufacture and market Valsartan Tablets, the generic version of Novartis’ Diovan.
Diovan is an angiotensin II receptor blocker indicated for the treatment of heart failure (NYHA Class II–IV). To reduce cardiovascular mortality in stable post-MI patients with left ventricular failure or dysfunction and hypertension. Diovan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.
RELATED: Hypertension Treatments: ARBs
Valsartan Tablets will be available in 40mg, 80mg, 160mg, and 320mg strengths.
For more information call (609) 720-9200 or visit Ranbaxy.com.
